ROCHE HLDG DR (RHO5 HM) stock market data APIs
€276.5975
-5.81(-2.1%)
as of May 16, 2025
Try our APIs with
free plan!
ROCHE HLDG DR Financial Data Overview
There is no Profile data available for RHO5.HM.
Prev. Close
276.5975
Open
270.7884
High
276.5975
Low
270.7884
52 wk Range
235.4067-293.3
Market Cap
312 681 M
Dividends (Yield)
0.0415
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ROCHE HLDG DR data using free add-ons & libraries
Get ROCHE HLDG DR Fundamental Data
ROCHE HLDG DR Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ROCHE HLDG DR News
New
Trump Trade: Trump asks Apple to stop building iPhone plants in India
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fl...
Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis
F. Hoffmann-La Roche Ltd The VENTANA MET (SP44) RxDx Assay detects the MET (also known as c-Met) protein, which is over-expressed in some patients with non-squamous non-small cell lung cancer (NSQ-NS...
Q1 2025 Lineage Cell Therapeutics Inc Earnings Call
Participants Ioana Hone; Investor Relations; Lineage Cell Therapeutics Inc Brian Culley; Chief Executive Officer, Director; Lineage Cell Therapeutics Inc Jill Howe; Chief Financial Officer; Lineage...
Roche says Trump's drug price order threatens its $50 billion US investment plans
LONDON (Reuters) -U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United States, the company said on Wednesday. Trump's order, si...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
